The FDA's Molecular and Clinical Genetics Panel voted 5-4 here Wednesday, with one abstention, that the benefits outweighed the risks for use of Epigenomics' Epi proColon to screen patients who are defined as average risk for colorectal cancer by current screening guidelines. The vote went in favor of adequate evidence of safety (9-0, with one abstention), and against adequate evidence of effectiveness (5-6), with panel chair Ronald Pryzgodzki, MD, acting director of biomedical laboratory R&D within the Department of Veterans Affairs, voting against adequate evidence of effectiveness to break the tie. The FDA is not obliged to go along with recommendations from its advisory committees, but it usually does.
Hoffen wir mal dass die FDA Lobby grünes Licht gibt
|